The universal short-term embolizate

Embocept®S is the universal short-term embolizate – your ideal combination partner for optimization of locoregional tumor therapy (TACE).

The ideal combination partner for optimization of locoregional cancer treatment in HCC patients

The advantages of EmboCept®S

  • Guideline-compliant treatment of HCC patients
  • Significant increase in overall survival
  • Significant increase in progression-free survival
  • Very good tolerability
  • Flexibility in treatment type and procedure
  • Simple handling in treatment use

EmboCept®S represents simple and flexible application and can be combined with any chemotherapy. 


  • Flexible and sediments slowly
  • Simple application
  • Endogenous degradation with a half-life of approx. 35 min
  • Collateral formation of tumor vessels can be excluded to a great extent
  • Dosage recommendation of 300 – 600 mg per patient 

         – Adjust exact dosage to individual patient
         – Determined by monitoring during imaging procedure

  • Repeated applications possible short intervals
  • Can be combined with all systemic anti-tumor therapies such as chemotherapies, antibodies, vaccines, cytokines, etc.

Medaid Solutions Pte Ltd is proud to be the exclusive distributor for PharmaCept in Singapore and Malaysia.

 Please feel free to contact us for more information at enquiry@medaid.com.sg